research
The Cell Therapy Preserved Two Kinds of Muscle
A phase III trial reported slower skeletal decline and preserved heart function in Duchenne muscular dystrophy.
Summary
A phase III trial reported slower skeletal decline and preserved heart function in Duchenne muscular dystrophy.
Cedars-Sinai investigators report that the investigational cell therapy deramiocel preserved cardiac function and slowed muscle decline in boys and young men with Duchenne muscular dystrophy in a phase III trial published in The Lancet. The result is clinically significant, but the therapy remains investigational and the release does not substitute for regulatory review or long-term safety follow-up.
Why it matters
A phase III trial reported slower skeletal decline and preserved heart function in Duchenne muscular dystrophy.
Limits and context
- The result is clinically significant, but the therapy remains investigational and the release does not substitute for regulatory review or long-term safety follow-up.
Key claims
A phase III trial reported slower skeletal decline and preserved heart function in Duchenne muscular dystrophy.
Qualification: The result is clinically significant, but the therapy remains investigational and the release does not substitute for regulatory review or long-term safety follow-up.
Evidence: source-2026-07-30-013
Sources
- Cedars-Sinai via Newswise: Phase III trial of deramiocel for Duchenne muscular dystrophyCedars-Sinai · secondary reporting
Corrections
No corrections have been recorded for this story.